ProShares Ultra Nasdaq Biotechnology Company profile
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. This ETF offers 2x daily long leverage to the broad-based NASDAQ Biotechnology Index, making it a powerful tool for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies. Investors should note that BIB’s leverage resets on a daily basis, which results in compounding of returns when held for multiple periods.Latest shares articles
ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
14:15, 16 October 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:41, 11 September 2024
Stocks struggle for direction as US jobs data fails to give assurance
Traders struggle to find a direction as the latest US jobs data gives a mixed picture heading into the FOMC September meeting.
13:32, 6 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
09:13, 29 August 2024
Ratings and Reviews
Ratings and Reviews
